It has been one year since GlaxoSmithKline''s gene therapy Strimvelis for treating ADA- deficient Severe combined immunodeficiency (ADA-SCID) has been approved for sale in Europe. However, the cost of the treatment which amounts to 594,000 Euros has limited its sale. The National Institute for Health and Care Excellence (NICE) has in an unprecedented manner approved GSK''s pricey gene therapy, Strimvelis, as an option to treat the rare immune deficiency condition.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer